1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Uteng, M. Hauge, H.H. Markwick, P.R. Fimland, G. Mantzilas, D. Nissen-Meyer, J. Muhle-Goll, C. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 42 11417 10.1021/BI034572I 14516192 Three-Dimensional Structure in Lipid Micelles of the Pediocin-Like Antimicrobial Peptide Sakacin P and a Sakacin P Variant that is Structurally Stabilized by an Inserted C-Terminal Disulfide Bridge 2003 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 4441.817 BACTERIOCIN SAKACIN P 1 man polymer SAKACIN 674 no no KYYGNGVHCGKHSCTVDWGTAIGNIGNNAAANWATGGNAGWNK KYYGNGVHCGKHSCTVDWGTAIGNIGNNAAANWATGGNAGWNK A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n LB790 sample 1599 LACTOBACILLUS SAKE LB790/PMLS114 1599 LACTOBACILLUS SAKE LB790 LB790/PMLS114 PMG36E PMLS114 repository Initial release Version format compliance Version format compliance 1 0 2003-09-22 1 1 2011-05-08 1 2 2011-07-13 SAKACIN P VARIANT THAT IS STRUCTURALLY STABILIZED BY AN INSERTED C-TERMINAL DISULFIDE BRIDGE. THREE-DIMENSIONAL STRUCTURE IN LIPID MICELLES OF THE PEDIOCIN-LIKE ANTIMICROBIAL PEPTIDE SAKACIN P. PDBE Y PDBE 2003-04-25 REL BACTERICIDAL ACTIVITY; INHIBITS LISTERIA AND MANY LACTOBACILLI SPECIES. THE SEQUENCE IS DESCRIBED IN J. BACTERIOL. 182, 2643-2648 THE STRUCTURES WERE DETERMINED USING A COMBINATION OF 1H NMR SPECTROSCOPIC METHODS FOLLOWED BY DISTANCE GEOMETRY/SIMULATED ANNEALING CALCULATIONS. LEAST RESTRAIN VIOLATION AND OVERALL ENERGY 50 10 NOESY TOCSY 2.8 pH 298 K AMBER 6, SAN FRANCISCO, UNIVERSITY OF CALIFORNIA, 1999. MOLECULAR DYNAMICS/ SIMULATED ANNEALING 1 90% TFE,0.1% TFA, 10% D2O,1MM PEPTIDE CASE, D.A., PEARLMAN, D.A., CALDWELL, III, J.C., ET AL. refinement AMBER 6 structure solution ARIA structure solution AMBER 500 Bruker DRX 600 Bruker DRX LYS 1 n 1 LYS 1 A TYR 2 n 2 TYR 2 A TYR 3 n 3 TYR 3 A GLY 4 n 4 GLY 4 A ASN 5 n 5 ASN 5 A GLY 6 n 6 GLY 6 A VAL 7 n 7 VAL 7 A HIS 8 n 8 HIS 8 A CYS 9 n 9 CYS 9 A GLY 10 n 10 GLY 10 A LYS 11 n 11 LYS 11 A HIS 12 n 12 HIS 12 A SER 13 n 13 SER 13 A CYS 14 n 14 CYS 14 A THR 15 n 15 THR 15 A VAL 16 n 16 VAL 16 A ASP 17 n 17 ASP 17 A TRP 18 n 18 TRP 18 A GLY 19 n 19 GLY 19 A THR 20 n 20 THR 20 A ALA 21 n 21 ALA 21 A ILE 22 n 22 ILE 22 A GLY 23 n 23 GLY 23 A ASN 24 n 24 ASN 24 A ILE 25 n 25 ILE 25 A GLY 26 n 26 GLY 26 A ASN 27 n 27 ASN 27 A ASN 28 n 28 ASN 28 A ALA 29 n 29 ALA 29 A ALA 30 n 30 ALA 30 A ALA 31 n 31 ALA 31 A ASN 32 n 32 ASN 32 A TRP 33 n 33 TRP 33 A ALA 34 n 34 ALA 34 A THR 35 n 35 THR 35 A GLY 36 n 36 GLY 36 A GLY 37 n 37 GLY 37 A ASN 38 n 38 ASN 38 A ALA 39 n 39 ALA 39 A GLY 40 n 40 GLY 40 A TRP 41 n 41 TRP 41 A ASN 42 n 42 ASN 42 A LYS 43 n 43 LYS 43 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N TYR 3 A N TYR 3 A O VAL 7 A O VAL 7 1 A A HIS SER 12 13 -149.01 1 A A CYS THR 14 15 -145.32 1 A A ALA ASN 31 32 127.23 1 A A TRP ALA 33 34 137.42 3 A A VAL ASP 16 17 129.11 3 A A ASP TRP 17 18 -148.77 3 A A ASN ASN 27 28 145.66 4 A A GLY VAL 6 7 -146.75 4 A A ALA ASN 31 32 132.24 6 A A SER CYS 13 14 -143.08 6 A A ALA ALA 30 31 148.79 6 A A GLY ASN 37 38 -146.35 9 A A ALA ASN 31 32 142.25 9 A A ASN TRP 32 33 147.44 10 A A ALA ALA 30 31 148.05 3 A TYR 3 0.080 SIDE CHAIN 4 A TYR 2 0.075 SIDE CHAIN 4 A TYR 3 0.084 SIDE CHAIN 5 A TYR 2 0.087 SIDE CHAIN 2 11.88 1.90 113.70 125.58 A A A CA CB CG TRP TRP TRP 18 18 18 N 4 -6.05 0.60 121.00 114.95 A A A CB CG CD2 TYR TYR TYR 2 2 2 N 4 3.74 0.60 121.00 124.74 A A A CB CG CD1 TYR TYR TYR 2 2 2 N 6 8.36 1.10 114.20 122.56 A A A CA CB SG CYS CYS CYS 9 9 9 N 1 A ASN 5 48.17 -87.01 1 A LYS 11 -143.66 -39.96 1 A CYS 14 -45.51 94.01 1 A VAL 16 63.79 -70.70 1 A ASP 17 -173.77 -6.35 1 A TRP 33 65.73 -30.68 1 A ALA 34 -59.68 -9.65 1 A THR 35 80.79 69.67 2 A TYR 3 100.56 -82.32 2 A ASN 5 31.70 73.60 2 A HIS 12 -143.16 37.43 2 A CYS 14 71.40 74.38 2 A THR 15 -59.13 173.40 2 A THR 35 -124.62 -79.15 3 A ASN 5 26.28 -91.45 3 A HIS 12 -136.70 -54.43 3 A ALA 34 -146.25 -16.57 4 A TYR 2 -67.03 -95.54 4 A ASN 5 -136.85 -54.38 4 A VAL 7 -53.02 -95.85 4 A HIS 8 106.60 23.99 4 A HIS 12 -153.75 67.73 4 A THR 15 -64.16 97.41 4 A ASP 17 120.97 -25.89 4 A TRP 18 -62.90 22.10 4 A ALA 30 -56.30 -9.22 4 A THR 35 -132.08 -52.71 5 A TYR 2 -83.24 -123.98 5 A TYR 3 47.72 -16.51 5 A ASN 5 38.14 68.07 5 A VAL 7 58.84 167.60 5 A HIS 12 -151.94 -71.38 5 A CYS 14 -74.81 36.67 5 A VAL 16 52.01 19.95 5 A ASP 17 49.99 16.34 5 A ASN 38 54.81 -77.93 5 A TRP 41 -59.96 97.48 6 A LYS 11 -133.49 -56.97 6 A HIS 12 -74.91 -152.34 6 A VAL 16 -69.81 28.22 6 A ASP 17 55.92 -2.60 6 A TRP 33 28.47 -66.65 6 A THR 35 -148.84 44.61 6 A ASN 38 44.72 -40.03 6 A ASN 42 -68.53 82.17 7 A HIS 8 48.98 78.55 7 A SER 13 -85.34 -92.11 7 A VAL 16 45.67 -110.81 7 A ALA 34 -146.04 -24.28 8 A ASN 5 40.74 -92.64 8 A SER 13 -102.49 62.12 8 A CYS 14 65.74 -38.30 8 A THR 15 59.17 -81.92 8 A VAL 16 57.67 -5.70 8 A ASP 17 59.25 18.20 8 A THR 35 -138.24 -71.28 8 A ASN 42 48.81 19.62 9 A LYS 11 66.23 -53.72 9 A ASP 17 -176.43 -42.41 9 A TRP 18 -79.67 22.46 9 A TRP 33 32.63 -72.56 9 A THR 35 -149.72 -25.19 9 A ASN 38 -121.88 -86.67 10 A VAL 7 -141.79 -60.72 10 A HIS 8 51.13 -77.43 10 A CYS 9 64.38 -47.20 10 A HIS 12 -162.29 -53.03 10 A CYS 14 -65.94 76.15 10 A VAL 16 58.35 -46.76 10 A ASP 17 126.76 -3.37 10 A ALA 30 -59.11 -9.30 10 A ALA 31 -111.11 -71.03 10 A ALA 34 -144.76 -23.72 10 A THR 35 -133.82 -37.35 BACTERIOCIN SAKACIN P Three-dimensional structure in lipid micelles of the pediocin-like antimicrobial peptide sakacin P. 1 N N A TRP 18 A TRP 18 HELX_P A TRP 33 A TRP 33 1 1 16 disulf 2.034 A CYS 9 A SG CYS 9 1_555 A CYS 14 A SG CYS 14 1_555 ANTIBIOTIC PEDIOCIN-LIKE BACTERIOCINS, ANTIMICROBIAL PEPTIDES, SAKACIN P, ANTIBIOTIC A ASN 5 A ASN 5 2 A GLY 6 A GLY 6 -9.16 A TYR 3 A TYR 3 4 A GLY 4 A GLY 4 4.17 A ASN 5 A ASN 5 7 A GLY 6 A GLY 6 -7.33 A GLY 36 A GLY 36 7 A GLY 37 A GLY 37 -7.69 SAKP_LACSK UNP 1 P35618 19 61 1OG7 1 43 P35618 A 1 1 43 2 anti-parallel A TYR 2 A TYR 2 A GLY 4 A GLY 4 A VAL 7 A VAL 7 A HIS 8 A HIS 8 1 P 1